Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions

Sangeeta T Mahajan, MD
Section Editor
Linda Brubaker, MD, FACOG
Deputy Editor
Kristen Eckler, MD, FACOG


Botulinum neurotoxin (BoNT) is a potent neurotoxin that is used for a variety of therapeutic indications (eg, dystonia, achalasia). Many clinicians are familiar with use of BoNT therapy for bladder and urethral dysfunction in patients with neurologic disorders (eg, spinal cord injury, multiple sclerosis). This agent is now gaining popularity for treatment of otherwise healthy patients with overactive bladder syndrome, benign prostatic hyperplasia, painful bladder syndrome/interstitial cystitis, and urinary retention following anti-incontinence surgery.

Use of BoNT for treatment of non-neurogenic lower urinary tract dysfunction is reviewed here. Treatment of neurogenic lower urinary tract dysfunction, other treatments for urgency incontinence and urinary retention, and the pharmacology of BoNT are discussed separately. (See "Chronic complications of spinal cord injury and disease" and "Symptom management of multiple sclerosis in adults" and "Management and prognosis of cerebral palsy" and "Treatment of urinary incontinence in women".)


A brief overview of the pharmacology of BoNT is presented here.

Mechanism — BoNT is produced by Clostridium botulinum, a gram-positive, anaerobic bacterium. BoNT acts by inhibiting calcium-mediated release of acetylcholine vesicles at the pre-synaptic neuromuscular junction in peripheral nerve endings [1]. This results in temporary flaccid muscle paralysis.

Formulations — Seven serologic forms of BoNT exist, including A, B, C, D, E, F, and G2, although only serotypes A and B are commercially available.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 03, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Moynihan BG. I. Mesenteric Cysts. Ann Surg 1897; 26:1.
  2. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003; 44:165.
  3. Botulinum toxin type A injection. US Food and Drug Administration (FDA) approved product information. Revised August 2015. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300 (Accessed on February 01, 2016).
  4. Binder WJ, Brin MF, Blitzer A, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon 2002; 48:323.
  5. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990; 71:24.
  6. Sahai A, Dowson C, Khan MS, et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010; 75:552.
  7. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167.
  8. OnabotulinumtoxinA prescribing information 01/18/2013. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist.
  9. Hsiao SM, Lin HH, Kuo HC. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. PLoS One 2016; 11:e0147137.
  10. Makovey I, Davis T, Guralnick ML, O'Connor RC. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability. Neurourol Urodyn 2011; 30:1538.
  11. Chohan N, Hilton P, Brown K, Dixon L. Efficacy and duration of response to botulinum neurotoxin A (onabotulinumA) as a treatment for detrusor overactivity in women. Int Urogynecol J 2015; 26:1605.
  12. Miotla P, Futyma K, Cartwright R, et al. Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery. Int Urogynecol J 2016; 27:393.
  13. Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011; :CD005493.
  14. Visco AG, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med 2012; 367:1803.
  15. Herschorn S, Kohan A, Aliotta P, et al. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. J Urol 2017; 198:167.
  16. Nitti VW, Ginsberg D, Sievert KD, et al. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol 2016; 196:791.
  17. Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005; 174:1873.
  18. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180:217.
  19. Flynn MK, Amundsen CL, Perevich M, et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009; 181:2608.
  20. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177:2231.
  21. Miotla P, Cartwright R, Skorupska K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk? Int Urogynecol J 2017; 28:845.
  22. Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005; 48:984.
  23. FDA information for prescribers. Interstim device. Medtronic. August, 2008. http://www.accessdata.fda.gov/cdrh_docs/pdf8/P080025c.pdf.
  24. van der Wilt AA, van Wunnik BP, Sturkenboom R, et al. Sacral neuromodulation in children and adolescents with chronic constipation refractory to conservative treatment. Int J Colorectal Dis 2016; 31:1459.
  25. Sharma A, Liu B, Waudby P, Duthie GS. Sacral neuromodulation for the management of severe constipation: development of a constipation treatment protocol. Int J Colorectal Dis 2011; 26:1583.
  26. Rydningen MB, Dehli T, Wilsgaard T, et al. Sacral neuromodulation for faecal incontinence following obstetric sphincter injury - outcome of percutaneous nerve evaluation. Colorectal Dis 2017; 19:274.
  27. Alonso Guardo L, Cano Gala C, Sánchez Poveda D, et al. Caudal Neuromodulation with the Transforaminal Sacral Electrode (InterStim®): Experience in a Pain Center Regarding 12 Implants. Korean J Pain 2016; 29:23.
  28. Peters KM, Killinger KA, Jaeger C, Chen C. Pilot Study Exploring Chronic Pudendal Neuromodulation as a Treatment Option for Pain Associated with Pudendal Neuralgia. Low Urin Tract Symptoms 2015; 7:138.
  29. Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. JAMA 2016; 316:1366.
  30. Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006; 175:835.
  31. Siddiqui NY, Amundsen CL, Visco AG, et al. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 2009; 182:2799.
  32. Noblett KL, Dmochowski RR, Vasavada SP, et al. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome. Neurourol Urodyn 2017; 36:727.
  33. Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006; 68:993.
  34. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009; 55:100.
  35. Natale F, La Penna C, Saltari M, et al. Voiding dysfunction after anti-incontinence surgery. Minerva Ginecol 2009; 61:167.
  36. FitzGerald MP, Brubaker L. The etiology of urinary retention after surgery for genuine stress incontinence. Neurourol Urodyn 2001; 20:13.
  37. Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn 2005; 24:2.
  38. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004; 171:2128.
  39. Smith CP, O'Leary M, Erickson J, et al. Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:185.
  40. Emmerson J. Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis. Mov Disord 1994; 9:367.
  41. Schurch B, Stöhrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164:692.
  42. Harper M, Popat RB, Dasgupta R, et al. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003; 92:325.
  43. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63:868.
  44. Schulte-Baukloh H, Knispel HH. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2005; 95:454.
  45. Apostolidis A, Dasgupta R, Fowler CJ, Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2005; 96:917.
  46. Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 2006; 67:232.
  47. Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007; 178:1359.
  48. Karsenty G, Elzayat E, Delapparent T, et al. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007; 177:1011.
  49. Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342:665.
  50. Greene P, Fahn S. Development on antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: Botulinum and tetanus neurotoxins: Neurotransmission and biomedical aspects, DasGupta B (Ed), Plenum Press, New York 1993.
  51. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9:213.
  52. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6:S146.
  53. Del Popolo G. Botulinum-A toxin in the treatment of detrusor hyperreflexia. Neurourol Urodyn 2001; 20:522.
  54. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm175011.htm (Accessed on March 17, 2010).